A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) inhibitors have been reported to prevent the release of NLGN3145 and are currently being tested in a Phase 1 clinical trial for high grade gliomas (NCT04295759). This evidence concerns the gene ADAM10 and central nervous system cancer.